Sant Ferran 74
Cornellà de Llobregat 08940
Spain
34 93 515 13 13
https://www.oryzon.com
Settore/i:
Settore:
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, CEO & President | 58k | N/D | N/D |
Mr. Enric Rello Condomines | Director of Operations, COO & CFO | N/D | N/D | N/D |
Mr. Jordi Xaus Pey | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Xavier Perpinya Ribera | Head of Internal Audit & Compliance | N/D | N/D | N/D |
Mr. Emili Torrell Cortada | Chief Business Development Officer | N/D | N/D | N/D |
Ms. Neus Virgili Bernado | Chief Intellectual Property Officer | N/D | N/D | N/D |
Dr. Michael Thomas Ropacki Ph.D. | Chief Medical Officer of CNS | N/D | N/D | N/D |
Ms. Sonia Paloma Gutierrez Bezon | Chief of Clinical Operations | N/D | N/D | N/D |
Dr. Ana Limon | Senior Vice President of Clinical Development & Global Medical Affairs | N/D | N/D | N/D |
Dr. Douglas V. Faller M.D., Ph.D. | Global Chief Medical Officer | N/D | N/D | N/D |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
L'ISS Governance QualityScore di Oryzon Genomics S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.